文献速递肝病消化道肿瘤与早癌

GLP-1受体激动剂联合SGLT-2抑制剂与MASLD合并2型糖尿病患者的肝脏及心血管重大不良结局风险

GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes.
PubMed 文献 · Hepatology · 2026-04-23

该目标试验模拟研究基于美国MarketScan数据库,比较GLP-1受体激动剂联合SGLT-2抑制剂与单药治疗在MASLD合并2型糖尿病患者中的效果。结果显示,联合治疗较单用GLP-1受体激动剂或SGLT-2抑制剂均与主要肝脏不良结局和主要心血管不良事件风险降低相关。

要点

  • 联合治疗较单用GLP-1受体激动剂显著降低主要肝脏不良结局和主要心血管不良事件风险。
  • 联合治疗较单用SGLT-2抑制剂同样显著降低主要肝脏不良结局和主要心血管不良事件风险。
  • 中位随访约6个月,联合治疗显示出短期获益,但长期效果需进一步验证。

核心结论

  • 在MASLD合并2型糖尿病患者中,GLP-1受体激动剂联合SGLT-2抑制剂较单用任一药物与主要肝脏不良结局和主要心血管不良事件风险降低相关。

研究设计与样本

  • 目标试验模拟研究,使用美国MarketScan数据库,通过倾向性评分匹配构建队列。
  • 比较联合治疗组4606例与单用GLP-1受体激动剂组18424例,以及联合治疗组5368例与单用SGLT-2抑制剂组21472例。
  • 采用Cox回归模型进行在治分析(on-treatment design)。

主要发现

  • 与单用GLP-1受体激动剂相比,联合治疗与主要肝脏不良结局风险降低39%相关[HR 0.61 (95% CI 0.49-0.77)],中位随访6.3个月。
  • 与单用GLP-1受体激动剂相比,联合治疗与主要心血管不良事件风险降低35%相关[HR 0.65 (95% CI 0.60-0.70)]。
  • 与单用SGLT-2抑制剂相比,联合治疗与主要肝脏不良结局风险降低43%相关[HR 0.57 (95% CI 0.46-0.69)],中位随访6.0个月。
  • 与单用SGLT-2抑制剂相比,联合治疗与主要心血管不良事件风险降低20%相关[HR 0.80 (95% CI 0.75-0.86)]。

临床怎么用

  • 对于MASLD合并2型糖尿病患者,可考虑GLP-1受体激动剂与SGLT-2抑制剂联合治疗以降低肝脏和心血管不良结局风险。

局限性

  • 本研究为观察性目标试验模拟研究,可能存在未测量混杂因素。
  • 中位随访时间较短(约6个月),长期获益和安全性需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors individually benefit patients with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to evaluate the effect of GLP-1 receptor agonist-SGLT-2 inhibitor combination on the risk of major adverse liver and cardiovascular outcomes compared with either agent alone among patients with MASLD and type 2 diabetes (T2D). APPROACH AND RESULTS: This is a target trial emulation study using data from U.S. MarketScan databases. Propensity score-matched cohorts were built to compare (1) 4606 patients who received GLP-1 receptor agonist-SGLT-2 inhibitor combination with 18,424 who received only GLP-1 receptor agonist, and (2) 5368 patients who received this combination with 21,472 who received only SGLT-2 inhibitors. Cox regression models were conducted in on-treatment designs. Compared with GLP-1 receptor agonists, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a 39% lower risk of major adverse liver outcomes [HR 0.61 (95% CI 0.49-0.77)] and a 35% lower risk of major adverse cardiovascular events [HR 0.65 (0.60-0.70)] during a median follow-up of 6.3 months. Compared with SGLT-2 inhibitors, the combination was associated with a 43% lower risk of major adverse liver outcomes [HR 0.57 (0.46-0.69)] and a 20% lower risk of major adverse cardiovascular events [HR 0.80 (0.75-0.86)] during a median follow-up of 6.0 months. CONCLUSIONS: In this study, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a lower risk of major adverse liver and cardiovascular outcomes compared with either agent alone among patients with MASLD and T2D.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Mao X, Fan H, Yuen MF, et al. GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes. Hepatology. 2026. PMID: 42029657. doi:10.1097/HEP.0000000000001771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。